Call Us: 1.800.873.5297

By

New Research Suggests that Testosterone Drugs Linked to Increased Risk of Heart Attacks, Strokes

Testosterone is used in men and boys to treat conditions caused by a lack of this hormone. Use of testosterone drugs has increased over the past decade, particularly in the United States, with dramatic shifts from injections to gels. Sales of testosterone gels and creams have dramatically increased despite the fact that long-term effects associated […]

By

EMA Investigates whether Emergency Contraceptives are Effective for Overweight Women

The European Medicines Agency (EMA), the regulatory authority in Europe similar to the United States Food and Drug Administration (FDA), is investigating whether emergency contraceptives, known as the “morning-after pill”, are effective in women who are overweight or obese. On January 24, 2014, the EMA issued a statement indicating that they have “started a review […]

By

Actos® Lawsuit Update: First Actos® Trial in Federal Court Begins

The first trial in the Multidistrict Litigation In re: Actos® (Pioglitazone) Products Liability Litigation, MDL 2299, begins today, January 27, 2014 with opening statements expected to occur on February 3, 2014. The Actos® Multidistrict Litigation (MDL 2299) is currently pending in the United States District Court for the Western District of Louisiana before The Honorable […]

By

FDA Warns of Dangers associated with Excessive Use of Laxative Products

On January 8, 2014, the FDA issued a Safety Announcement “warning that using more than one dose in 24 hours of over-the-counter sodium phosphate drugs to treat constipation can cause rare but serious harm to the kidneys and heart, and even death.” The sodium phosphate drug products at issue are marketed under the brand-name Fleet, […]

By

FDA Issues Class I Recall of Certain Ventilators due to Software Problem

On December 16, 2013, the FDA issued a Class I Recall of the Covidien Puritan Bennett™ 840 Series Ventilator due to a software problem. As defined by the FDA, “Class I Recalls are the most serious type of recall and involve situations in which there is reasonable probability that use of these products will cause […]

By

FDA Restricts Drugs with High Doses of Acetaminophen

In January 2011, the FDA requested that manufacturers limit drug products containing acetaminophen to no more than 325 mg in each tablet or capsule by January 14, 2014. FDA held true to the request and will soon withdraw approval for any medications containing more than 325 mg of acetaminophen. On January 14, 2014, the FDA issued […]

By

Transvaginal Mesh MDL Lawsuit Update: C.R. Bard Denied Request to Exclude Certain Documents at Trial

Law 360 reports that The Honorable Judge Joseph Goodwin, who presides over the C.R. Bard Multidistrict Litigation (MDL) pending in the Southern District of West Virginia, has denied C.R. Bard’s motion requesting the exclusion of an employee’s proposed changes to vaginal mesh products as evidence based on the finding that they touched on the issue […]

By

Schlichter, Bogard & Denton, LLP Attorney Kristine Kraft Featured in Huffington Post Article on Dangers of NuvaRing

A recent exposé by The Huffington Post, titled Side Effects May Include Death: The Story of the Biggest Advance in Birth Control Since the Pill, discusses the dangers allegedly posed by NuvaRing®, one of the most popular forms of birth control in the world. More than 2,000 cases are currently pending in the United States […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.